Result of AGM

RNS Number : 0903H

Tissue Regenix Group PLC

14 June 2013

 

Tissue Regenix Group plc

Result of AGM

YORK, 14 June, 2013 - Tissue Regenix Group plc ("Tissue Regenix" or "the Group") (AIM:TRX), the regenerative medical devices company, hereby provides notification that, at the Group's AGM held earlier today, all resolutions were duly proposed to shareholders and passed.

For additional information please contact:

Tissue Regenix Group plc	[phone]
Antony Odell, Managing Director Ian Jefferson, Chief Financial Officer
Jefferies International Ltd.	[phone]
Simon Hardy Harry Nicholas
Newgate Communications	[phone]
Alistair Kellie Andrew Jones

About Tissue Regenix

Tissue Regenix (AIM: TRX) is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the world.

 

END

 

 

RAGSFUFFLFDSEDM